Investing.comDoubao · 实盘不做把握 8/10不做原因:风险收益比不佳
北京时间·🕒 发布 20:52:27·⟳ 抓取 20:52:53 +26s·⚡ 决策 10-19 20:55:21 +2m28s·7.9 天前
OneMedNet宣布第12个渠道合作方分销去标识化临床数据，未披露对方身份及任何金额
消息量级不足且无edge：未具名合作方、无任何财务条款的第12个例行渠道协议，属渠道扩张的公关式披露，不能建立收入或估值弹性；标的为约2,700万美元纳型亏损股，近20日下跌35.6%、处于明确下行通道，盘前仅千余股成交、微涨3%且无一手扩散，软催化不足以驱动正期望交易。
📄 原文Investing.com↗ 原文
OneMedNet signs 12th partner for real-world data distribution
MINNEAPOLIS - OneMedNet Corporation (NASDAQ:ONMD) announced today a channel partner agreement with a global provider of…
不做 OneMedNet Corporation（ONMD.US）
test
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
OneMedNet宣布第12个匿名渠道合作方分销临床数据，但无合作方名称、无金额、无采购承诺，属例行非实体渠道PR；叠加约2,700万美元亏损纳市值、股价20日跌35.6%的下行趋势，催化量级与可验证性均不足，回避。
🔎 新鲜度:最早出现 2026-10-19 · 扩散 low · price-in 风险 low ↗
关键理由
- 唯一直接标的的催化无名称、无金额、无承诺，且为第12个同类例行协议，无法估算任何收入/利润增量。
- 公司市值约2,674万美元、PE为负(-7.5)，近20日累计-35.6%、距52周高点-84%，软渠道PR难以扭转下行趋势。
主要风险
- 纳型小盘股的渠道新闻稿偶尔触发情绪性短线脉冲，但盘前仅1,078股、+3.1%，缺乏资金确认，追高风险大于机会。
- 合作方匿名意味着无法独立验证其客户覆盖与履约能力，后续若无订单/收入落地，催化易被证伪。
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`onemednet channel partner agreement de-identified clinical data pharmaceutical | onmd 12th channel partnership real-world data distribution`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续 - stock_quote 成功 stock_tools HTTP · 2,641 ms
{
原文全文
展开原文 · 1,809 字
MINNEAPOLIS - OneMedNet Corporation (NASDAQ:ONMD) announced today a channel partner agreement with a global provider of pharmaceutical intelligence and data solutions to distribute its de-identified clinical data to pharmaceutical customers worldwide.
The agreement represents OneMedNet’s 12th channel partnership, according to a press release statement. The partner, which OneMedNet did not name, will distribute the company’s U.S.-sourced clinical data to its existing pharmaceutical customer base.
OneMedNet provides real-world data sourced directly from healthcare providers. The data is de-identified at the source and delivered to support drug development, regulatory submissions, and commercial decisions by pharmaceutical companies.
The company’s network spans more than 2,300 sites and includes over 90 million patient journeys and 270 million studies. OneMedNet’s iRWD platform delivers datasets that include de-identified medical imaging alongside clinical records.
"First-party, direct-from-source data gives our partners confidence in the quality, provenance, and compliance of what they deliver to their customers," said Aaron Green, President and CEO of OneMedNet.
The global real-world data market is estimated at approximately $2.7 billion in 2026 and is projected to reach $7.1 billion by 2033, according to Coherent Market Insights cited in the release.
OneMedNet’s strategy involves extending commercial reach through distribution channels while maintaining direct control of data sourcing, curation, and de-identification. The company serves life sciences companies, medical device manufacturers, and AI developers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
OneMedNet signs 12th partner for real-world data distribution
The agreement represents OneMedNet’s 12th channel partnership, according to a press release statement. The partner, which OneMedNet did not name, will distribute the company’s U.S.-sourced clinical data to its existing pharmaceutical customer base.
OneMedNet provides real-world data sourced directly from healthcare providers. The data is de-identified at the source and delivered to support drug development, regulatory submissions, and commercial decisions by pharmaceutical companies.
The company’s network spans more than 2,300 sites and includes over 90 million patient journeys and 270 million studies. OneMedNet’s iRWD platform delivers datasets that include de-identified medical imaging alongside clinical records.
"First-party, direct-from-source data gives our partners confidence in the quality, provenance, and compliance of what they deliver to their customers," said Aaron Green, President and CEO of OneMedNet.
The global real-world data market is estimated at approximately $2.7 billion in 2026 and is projected to reach $7.1 billion by 2033, according to Coherent Market Insights cited in the release.
OneMedNet’s strategy involves extending commercial reach through distribution channels while maintaining direct control of data sourcing, curation, and de-identification. The company serves life sciences companies, medical device manufacturers, and AI developers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
OneMedNet signs 12th partner for real-world data distribution
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
9224eabece· 2026-10-19 20:55 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前